A recent clinical trial, PEACE-3 (EORTC 1333, n°NCT02194842), explored a new combination therapy for men with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones. Researchers tested whether adding radium-223 to standard enzalutamide plus androgen deprivation therapy (ADT) could improve outcomes.

The results are encouraging: patients receiving the combination lived longer without their cancer worsening and also showed improved overall survival compared with enzalutamide plus ADT alone. While there were slightly more bone fractures in the combination group, using bone-strengthening medication helped lower the risk, and most side effects were manageable.

This study suggests that combining enzalutamide and radium-223 could become a new treatment option for men with mCRPC in the bones, offering both longer survival and slower disease progression. Doctors may consider giving bone-protecting medication alongside this therapy to reduce fracture risks.

Read a Plain Language Summary, Taylor & Francis, here.

A pilot study by NYU Langone Health detected microplastics in 90% of prostate cancer tumours, with cancerous tissue containing 2.5 times more plastic than healthy tissue. These tiny particles, from everyday plastics in food, cosmetics, and clothing, can enter the body through food, air, or skin.
Researchers suggest microplastics may trigger chronic inflammation, potentially contributing to cancer development. The findings highlight the need for further research on how plastic exposure affects human health.

Read the full article here.

Metastatic prostate cancer is becoming increasingly treatable, but many patients eventually develop resistance to testosterone-lowering therapy. New treatments with unique mechanisms are urgently needed.

Promising options include PARP inhibitors like olaparib for patients with DNA repair defects, radioligand therapy such as 177Lu-PSMA that targets cancer cells directly, and novel hormonal drugs like opevesostat. Immunotherapy approaches, including antibody-drug conjugates (ifinatamab deruxtecan) and bispecific T-cell engagers (xaluritamig), are also showing early promise.

These innovations are paving the way for more effective, personalised care and improved outcomes.

Read the full article here, written by Dirk Wyndaele, prostate cancer patient, The Netherlands.

Europa Uomo is launching a new international project, “Living with Prostate Cancer,”  focusing on the impact of prostate cancer on sexuality, intimate relationships and family life. The purpose of this survey for member organisations is to ensure that the project is firmly based on the real needs of member organisations, patients and families across Europe.

This project brings visibility to issues that often remain in the background: how cancer affects relationships, sexuality and family life. It aims to provide patients and their loved ones with concrete tools for coping and adaptation, while developing a model that can be shared and implemented internationally. The project seeks to improve quality of life, strengthen families and offer hope.

Through this survey, we aim to better understand how prostate cancer affects living with prostate cancer, sexuality, couple relationships and family life, as well as the specific challenges faced by men living alone. We also seek to identify where current support is insufficient and which types of support are considered most useful in different countries.

The results will be used during the first year of the project’s concept development phase to define research questions, design content and support formats, and develop a digital platform, event models and an international dissemination framework. The core principle of the project is to listen to men and their loved ones — their experiences and needs guide all development work.

We kindly invite you to complete this short survey (5–7 minutes). The perspectives of member organisations are essential for shaping the content of the project and the solutions developed. Please forward this survey to as many persons inside your organisations as possible.

Thank you for your valuable contribution and continued collaboration.

On Saturday, 14 March 2026, join the EAU26 Prostate Cancer Run, a charity event powered by the EAU, Europa Uomo, and Bayer AG. Lace up for a sunrise run or a gentle walk along the scenic Thames and support prostate cancer research.

Choose a 4 km run or 2 km walk along the scenic Thames. All proceeds support Europa Uomo’s prostate cancer projects. Meet at 6:45 AM at Royal Victoria Square, London (Bag drop and runner’s vest included, Coffee and light refreshments after the finish).

Register: €20 individual, €300 team of 10 persons, patients & families free. Virtual participation welcome. Share your run with #EAU26pcarun and start your Saturday with endorphins and a cause!

See you at the start line!

More information + registration here.

The Dutch Cancer Society is investing €3.2 million in a five-year national pilot study to evaluate whether prostate cancer screening can be implemented responsibly and effectively in the Netherlands.

The study will invite 25,000 men aged 50–70 for a PSA blood test, using a risk-based approach in which only men with elevated risk are referred for further assessment, including MRI. The aim is to detect clinically significant cancers earlier while reducing overdiagnosis, unnecessary treatment, and overt testing.

The results will inform a cost-effectiveness analysis and support decision-making by the RIVM, the Ministry of Health, Welfare and Sport and the Health Council on whether a nationwide screening programme should be introduced.

On 4 February, WECAN Foundation launched a free online course on Patient Experience Data (PED) for patients, advocates, patient leaders, and anyone involved in cancer advocacy.

As patient experience and quality of life gain increasing importance in healthcare decision-making — including at the European Medicines Agency — the course aims to help patient communities build the skills needed to engage effectively in research, policy, and treatment discussions.

The course includes four interactive modules with case studies, practical tools, and resources. It is fully online, free, flexible, and open to all, with no research background required.

More info here.

On Saturday, February  28, 2026 at 6.00pm CET (12.00pm ET), the Active Surveillance Patients International (ASPI) is organizing a webinar where Dr. Mark Emberton, an internationally recognized leader in prostate cancer diagnosis and imaging, will explain how MRI has transformed biopsy decisions, where its limits remain, and how far prostate cancer assessment may move toward less invasive approaches.

More information and registration here.